Wang Xinyi, Li Jingwen, Liu Hanshu, Hu Xinyu, Lin Zhicheng, Xiong Nian
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Mclean Hospital, Harvard Medical School, Belmont, MA 02478, USA.
Microorganisms. 2023 Feb 24;11(3):580. doi: 10.3390/microorganisms11030580.
For three years, the novel coronavirus disease 2019 (COVID-19) pandemic, caused by infection of the SARS-CoV-2 virus, has completely changed our lifestyles and prepared us to live with this novel pneumonia for years to come. Given that pre-existing flu is caused by the influenza A virus, we have begun unprecedently co-coping with two different respiratory diseases at the same time. Hence, we draw a comparison between SARS-CoV-2 and influenza A virus based on the general characteristics, especially the main variants' history and the distribution of the two viruses. SARS-CoV-2 appeared to mutate more frequently and independently of locations than the influenza A virus. Furthermore, we reviewed present clinical trials on combined management against COVID-19 and influenza in order to explore better solutions against both at the same time.
三年来,由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染引发的2019年新型冠状病毒病(COVID-19)大流行彻底改变了我们的生活方式,并让我们做好了在未来数年与这种新型肺炎共存的准备。鉴于既往流感由甲型流感病毒引起,我们史无前例地开始同时应对两种不同的呼吸道疾病。因此,我们基于一般特征,特别是两种病毒主要变异株的演变历程及分布情况,对SARS-CoV-2和甲型流感病毒进行了比较。SARS-CoV-2似乎比甲型流感病毒变异更频繁,且不受地理位置影响。此外,我们回顾了目前针对COVID-19和流感联合治疗的临床试验,以探索同时更好地应对这两种疾病的解决方案。